Antalgic Effects of Well-being Treatments in Cancer Care (Well Being)

September 5, 2025 updated by: Centre Hospitalier de Valence

Antalgic Effects of Well-being Treatments in Cancer Care; Foot Reflexology, Socio-aesthetics, Sophrology, Singing

observational , Monocentric, study to assess antalgic effects of well-being treatment in cancer care.

Study Overview

Status

Completed

Conditions

Detailed Description

Contrary to supportive care, well-being care is imperfectly assessed. Well being care (WBC) consist on complementary programs, with no real consensus. Very few studies have rigorously evaluated its benefits

The objective of this study was to evaluate the impact of four well-being treatments (foot reflexology, socio-aesthetics, Sophrology and singing) provided in a healthcare facility

Study Type

Observational

Enrollment (Actual)

180

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
    • Drome
      • Valence, Drome, France, 26953
        • CH VALENCE

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients treated for a cancer in CH Valence, agree to participate on one of the 4 Well being treatments: foot reflexology, socio-aesthetics, sophrology and singing

Description

Inclusion Criteria:

  • all type of cancer treated at the general Hospital of Valence
  • patient agree to participate on Well being session: foot reflexology, socio-aesthetics, Sophrology and singing
  • Age ≥ 18 years
  • Affiliation to a Social security system
  • Patient who has given written consent signed before any specific procedure of the protocol

Exclusion Criteria:

  • Patient under guardianship, deprived of liberty, safeguard of justice
  • Patient presenting a serious psychiatric pathology that does not allow compliance with the completion of the scale (at the discretion of the investigator)
  • Refusal to participate in research

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain assesment
Time Frame: 1 immediately before well being treatment
numerical scale 0 to 10, with 0 being "no pain" and 10 being "the worst pain imaginable."
1 immediately before well being treatment
Pain assesment
Time Frame: 1 immediately after well being treatment
numerical scale 0 to 10, with 0 being "no pain" and 10 being "the worst pain imaginable."
1 immediately after well being treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier de Valence

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 22, 2020

Primary Completion (Actual)

September 30, 2021

Study Completion (Actual)

December 30, 2021

Study Registration Dates

First Submitted

July 6, 2022

First Submitted That Met QC Criteria

August 5, 2022

First Posted (Actual)

August 9, 2022

Study Record Updates

Last Update Posted (Estimated)

September 8, 2025

Last Update Submitted That Met QC Criteria

September 5, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RIPH-CHV-04

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe